BioPortfolio Limited Cancer Market Trends 2008

Summary
Introduction
Key disease markets
Key drug classes
Key products
Key companies
Key trends and opportunities

Chapter 1 Introduction
Global cancer market
Report overview

Methodology
Sources
Structure

Chapter 2 Key disease markets
Key cancer markets

Disease burden
Cancer incidence
Cancer mortality

Cancer epidemiology

Prostate cancer
Breast cancer
Lung and bronchus cancer
Colorectal cancer
Urinary bladder cancer
Non-Hodgkin's lymphoma
Melanoma
Kidney and renal pelvis cancer
Leukemia
Uterine corpus/endometrium (uterus) cancer

Cancer treatment-related disorders
Nausea and vomiting
Hematological disorders
Other cancer treatment side effects

Chapter 3 Key drug classes
Key drug classifications
Hormonals drug class

Leading hormonal drugs

Chemotherapeutics drug class

Leading chemotherapeutic drugs

Innovatives drug class

Leading innovative drugs

Selected adjuncts drug class

Leading selected adjunct drugs

Chapter 4 Key products
Leading products
Top 10 leading cancer drugs

Rituxan/MabThera (rituximab)
Herceptin (trastuzumab)
Aranesp (darbepoetin alfa)
Avastin (bevacizumab)
Gleevec/Glivec (imatinib)
Neulasta (pegfilgrastim)
Eprex/Procrit (epoetin alfa)
Taxotere (docetaxel)
Epogen (epoetin alfa)
Eloxatin (oxaliplatin)

Chapter 5 Key companies
Major cancer players
Leading companies

Amgen
Roche
Novartis
Genentech
Sanofi-Aventis
AstraZeneca
Johnson & Johnson
Pfizer
Eli Lilly
Merck

Chapter 6 Key trends and opportunities
Key disease market forecasts

Global markets
Cancer sites

Key drug class forecasts

Hormonals
Chemotherapeutics
Innovatives
Selected adjuncts

Key product forecasts

Key company forecasts

Amgen
Roche
Novartis
Genentech
Sanofi-Aventis
AstraZeneca
Johnson & Johnson
Pfizer
Eli Lilly
Merck

Appendix
Proprietary data sources

Product Trends Database
R&D Trends Database
Company Trends Database
Market Trends Database

List of Figures (Cancer Market Trends 2008 - 2012)

Figure 1: Global cancer market, 2003-2007
Figure 2: Report structure
Figure 3: Disease burden in seven major pharmaceutical markets, 2007
Figure 4: New cancer cases in the US, 2008
Figure 5: Cancer deaths in the US, 2008
Figure 6: Cancer epidemiology in seven major markets, 2007
Figure 7: Prostate cancer epidemiology in seven major markets, 2007
Figure 8: Breast cancer epidemiology in seven major markets, 2007
Figure 9: Lung and bronchus cancer epidemiology in seven major markets, 2007
Figure 10: Colorectal cancer epidemiology in seven major markets, 2007
Figure 11: Urinary bladder cancer epidemiology in seven major markets, 2007
Figure 12: Non-Hodgkin's lymphoma epidemiology in seven major markets, 2007
Figure 13: Melanoma epidemiology in seven major markets, 2007
Figure 14: Kidney and renal pelvis cancer epidemiology in seven major markets, 2007
Figure 15: Leukemia epidemiology in seven major markets, 2007
Figure 16: Uterine corpus/endometrium (uterus) cancer epidemiology in seven major markets, 2007
Figure 17: Global cancer market by drug class, 2007
Figure 18: Global cancer market by drug class, 2003-2007
Figure 19: Global cancer market trends by drug class, 2006-2007
Figure 20: Hormonals market, 2003-2007
Figure 21: Leading hormonal drugs by approval date, 1985-2007
Figure 22: Chemotherapeutics market, 2003-2007
Figure 23: Leading chemotherapeutic drugs by approval date, 1991-2007
Figure 24: Innovatives market, 2003-2007
Figure 25: Leading innovative drugs by approval date, 1983-2007
Figure 26: Selected adjuncts market, 2003-2007
Figure 27: Leading selected adjunct drugs by approval date, 1988-2007
Figure 28: Cancer blockbuster trends, 2006-2007
Figure 29: Top 10 cancer products by global sales, 2007
Figure 30: Top 10 companies by global cancer sales, 2007
Figure 31: Top 10 companies by global cancer market share, 2007
Figure 32: Top 10 companies by global cancer sales, 2006-2007
Figure 33: Cancer incidence forecasts by geographic market, 2007-2012
Figure 34: Cancer incidence forecasts by disease market, 2007-2012
Figure 35: Global cancer market forecast, 2003-2012
Figure 36: Global cancer market forecasts by drug class, 2003-2012
Figure 37: Top 10 cancer drugs by forecast sales, 2012
Figure 38: Rituxan/MabThera (rituximab) forecast sales, 2003-2012
Figure 39: Herceptin (trastuzumab) forecast sales, 2003-2012
Figure 40: Aranesp (darbepoetin alfa) forecast sales, 2003-2012
Figure 41: Avastin (bevacizumab) forecast sales, 2004-2012
Figure 42: Gleevec/Glivec (imatinib) forecast sales, 2003-2012
Figure 43: Neulasta (pegfilgrastim) forecast sales, 2003-2012
Figure 44: Eprex/Procrit (epoetin alfa) forecast sales, 2003-2012
Figure 45: Taxotere (docetaxel) forecast sales, 2003-2012
Figure 46: Epogen (epoetin alfa) forecast sales, 2003-2012
Figure 47: Eloxatin (oxaliplatin) forecast sales, 2003-2012
Figure 48: Forecast patent expiries by 2007 global sales, 2008-2017
Figure 49: Top ten companies by cancer sales trends, 2007-2012

List of Tables (Caner Market Trends 2008 -2012

Table 1: Global cancer market trends by drug class, 2005-2007
Table 2: Leading hormonal drugs, 2007
Table 3: Hormonals market trends, 2005-2007
Table 4: Leading chemotherapeutic drugs, 2007
Table 5: Chemotherapeutics market trends, 2005-2007
Table 6: Leading innovative drugs, 2007
Table 7: Innovatives market trends, 2005-2007
Table 8: Leading selected adjunct drugs, 2007
Table 9: Selected adjuncts market trends, 2005-2007
Table 10: Top 20 cancer products by global sales, 2005-2007
Table 11: Rituxan/MabThera (rituximab) profile, 2007
Table 12: Herceptin (trastuzumab) profile, 2007
Table 13: Aranesp (darbepoetin) profile, 2007
Table 14: Avastin (bevacizumab) profile, 2007
Table 15: Gleevec/Glivec (imatinib) profile, 2007
Table 16: Neulasta (pegfilgrastim) profile, 2007
Table 17: Eprex/Procrit (epoetin alfa) profile, 2007
Table 18: Taxotere (docetaxel) profile, 2007
Table 19: Epogen (epoetin alfa) profile, 2007
Table 20: Eloxatin (oxaliplatin) profile, 2007
Table 21: Top 10 companies by global cancer sales, 2005-2007
Table 22: Amgen profile, 2007
Table 23: Amgen cancer pipeline, 2007
Table 24: Roche profile, 2007
Table 25: Roche cancer pipeline, 2007
Table 26: Novartis profile, 2007
Table 27: Novartis cancer pipeline, 2007
Table 28: Genentech profile, 2007
Table 29: Genentech cancer pipeline, 2007
Table 30: Sanofi-Aventis profile, 2007
Table 31: Sanofi-Aventis cancer pipeline, 2007
Table 32: AstraZeneca profile, 2007
Table 33: AstraZeneca cancer pipeline, 2007
Table 34: Johnson & Johnson profile, 2006
Table 35: Johnson & Johnson cancer pipeline, 2007
Table 36: Pfizer profile, 2007
Table 37: Pfizer cancer pipeline, 2007
Table 38: Eli Lilly profile, 2007
Table 39: Eli Lilly cancer pipeline, 2007
Table 40: Merck profile, 2007
Table 41: Merck cancer pipeline, 2007
Table 42: Global cancer market forecasts by drug class, 2005-2012
Table 43: Top 10 cancer drugs forecasts, 2005-2012
Table 44: Top 10 companies by cancer sales forecasts, 2007-2012
Table 45: Top 56 cancer products by global pharmaceutical sales, 2005-2007
Table 46: Top 14 companies by global cancer sales, 2005-2007

	Cancer Market Trends 2008 - 2012
	Summary Introduction Key disease markets Key drug classes Key products Key companies Key trends and opportunities Chapter 1 Introduction Global cancer market Report overview Methodology Sources Structure Chapter 2 Key disease markets Key cancer markets Disease burden Cancer incidence Cancer mortality Cancer epidemiology Prostate cancer Breast cancer Lung and bronchus cancer Colorectal cancer Urinary bladder cancer Non-Hodgkin's lymphoma Melanoma Kidney and renal pelvis cancer Leukemia Uterine corpus/endometrium (uterus) cancer Cancer treatment-related disorders Nausea and vomiting Hematological disorders Other cancer treatment side effects Chapter 3 Key drug classes Key drug classifications Hormonals drug class Leading hormonal drugs Chemotherapeutics drug class Leading chemotherapeutic drugs Innovatives drug class Leading innovative drugs Selected adjuncts drug class Leading selected adjunct drugs Chapter 4 Key products Leading products Top 10 leading cancer drugs Rituxan/MabThera (rituximab) Herceptin (trastuzumab) Aranesp (darbepoetin alfa) Avastin (bevacizumab) Gleevec/Glivec (imatinib) Neulasta (pegfilgrastim) Eprex/Procrit (epoetin alfa) Taxotere (docetaxel) Epogen (epoetin alfa) Eloxatin (oxaliplatin) Chapter 5 Key companies Major cancer players Leading companies Amgen Roche Novartis Genentech Sanofi-Aventis AstraZeneca Johnson & Johnson Pfizer Eli Lilly Merck Chapter 6 Key trends and opportunities Key disease market forecasts Global markets Cancer sites Key drug class forecasts Hormonals Chemotherapeutics Innovatives Selected adjuncts Key product forecasts Rituxan/MabThera (rituximab) Herceptin (trastuzumab) Aranesp (darbepoetin alfa) Avastin (bevacizumab) Gleevec/Glivec (imatinib) Neulasta (pegfilgrastim) Eprex/Procrit (epoetin alfa) Taxotere (docetaxel) Epogen (epoetin alfa) Eloxatin (oxaliplatin) Forecast patent expiries Key company forecasts Amgen Roche Novartis Genentech Sanofi-Aventis AstraZeneca Johnson & Johnson Pfizer Eli Lilly Merck Appendix Proprietary data sources Product Trends Database R&D Trends Database Company Trends Database Market Trends Database List of Figures (Cancer Market Trends 2008 - 2012) Figure 1: Global cancer market, 2003-2007 Figure 2: Report structure Figure 3: Disease burden in seven major pharmaceutical markets, 2007 Figure 4: New cancer cases in the US, 2008 Figure 5: Cancer deaths in the US, 2008 Figure 6: Cancer epidemiology in seven major markets, 2007 Figure 7: Prostate cancer epidemiology in seven major markets, 2007 Figure 8: Breast cancer epidemiology in seven major markets, 2007 Figure 9: Lung and bronchus cancer epidemiology in seven major markets, 2007 Figure 10: Colorectal cancer epidemiology in seven major markets, 2007 Figure 11: Urinary bladder cancer epidemiology in seven major markets, 2007 Figure 12: Non-Hodgkin's lymphoma epidemiology in seven major markets, 2007 Figure 13: Melanoma epidemiology in seven major markets, 2007 Figure 14: Kidney and renal pelvis cancer epidemiology in seven major markets, 2007 Figure 15: Leukemia epidemiology in seven major markets, 2007 Figure 16: Uterine corpus/endometrium (uterus) cancer epidemiology in seven major markets, 2007 Figure 17: Global cancer market by drug class, 2007 Figure 18: Global cancer market by drug class, 2003-2007 Figure 19: Global cancer market trends by drug class, 2006-2007 Figure 20: Hormonals market, 2003-2007 Figure 21: Leading hormonal drugs by approval date, 1985-2007 Figure 22: Chemotherapeutics market, 2003-2007 Figure 23: Leading chemotherapeutic drugs by approval date, 1991-2007 Figure 24: Innovatives market, 2003-2007 Figure 25: Leading innovative drugs by approval date, 1983-2007 Figure 26: Selected adjuncts market, 2003-2007 Figure 27: Leading selected adjunct drugs by approval date, 1988-2007 Figure 28: Cancer blockbuster trends, 2006-2007 Figure 29: Top 10 cancer products by global sales, 2007 Figure 30: Top 10 companies by global cancer sales, 2007 Figure 31: Top 10 companies by global cancer market share, 2007 Figure 32: Top 10 companies by global cancer sales, 2006-2007 Figure 33: Cancer incidence forecasts by geographic market, 2007-2012 Figure 34: Cancer incidence forecasts by disease market, 2007-2012 Figure 35: Global cancer market forecast, 2003-2012 Figure 36: Global cancer market forecasts by drug class, 2003-2012 Figure 37: Top 10 cancer drugs by forecast sales, 2012 Figure 38: Rituxan/MabThera (rituximab) forecast sales, 2003-2012 Figure 39: Herceptin (trastuzumab) forecast sales, 2003-2012 Figure 40: Aranesp (darbepoetin alfa) forecast sales, 2003-2012 Figure 41: Avastin (bevacizumab) forecast sales, 2004-2012 Figure 42: Gleevec/Glivec (imatinib) forecast sales, 2003-2012 Figure 43: Neulasta (pegfilgrastim) forecast sales, 2003-2012 Figure 44: Eprex/Procrit (epoetin alfa) forecast sales, 2003-2012 Figure 45: Taxotere (docetaxel) forecast sales, 2003-2012 Figure 46: Epogen (epoetin alfa) forecast sales, 2003-2012 Figure 47: Eloxatin (oxaliplatin) forecast sales, 2003-2012 Figure 48: Forecast patent expiries by 2007 global sales, 2008-2017 Figure 49: Top ten companies by cancer sales trends, 2007-2012 List of Tables (Caner Market Trends 2008 -2012 Table 1: Global cancer market trends by drug class, 2005-2007 Table 2: Leading hormonal drugs, 2007 Table 3: Hormonals market trends, 2005-2007 Table 4: Leading chemotherapeutic drugs, 2007 Table 5: Chemotherapeutics market trends, 2005-2007 Table 6: Leading innovative drugs, 2007 Table 7: Innovatives market trends, 2005-2007 Table 8: Leading selected adjunct drugs, 2007 Table 9: Selected adjuncts market trends, 2005-2007 Table 10: Top 20 cancer products by global sales, 2005-2007 Table 11: Rituxan/MabThera (rituximab) profile, 2007 Table 12: Herceptin (trastuzumab) profile, 2007 Table 13: Aranesp (darbepoetin) profile, 2007 Table 14: Avastin (bevacizumab) profile, 2007 Table 15: Gleevec/Glivec (imatinib) profile, 2007 Table 16: Neulasta (pegfilgrastim) profile, 2007 Table 17: Eprex/Procrit (epoetin alfa) profile, 2007 Table 18: Taxotere (docetaxel) profile, 2007 Table 19: Epogen (epoetin alfa) profile, 2007 Table 20: Eloxatin (oxaliplatin) profile, 2007 Table 21: Top 10 companies by global cancer sales, 2005-2007 Table 22: Amgen profile, 2007 Table 23: Amgen cancer pipeline, 2007 Table 24: Roche profile, 2007 Table 25: Roche cancer pipeline, 2007 Table 26: Novartis profile, 2007 Table 27: Novartis cancer pipeline, 2007 Table 28: Genentech profile, 2007 Table 29: Genentech cancer pipeline, 2007 Table 30: Sanofi-Aventis profile, 2007 Table 31: Sanofi-Aventis cancer pipeline, 2007 Table 32: AstraZeneca profile, 2007 Table 33: AstraZeneca cancer pipeline, 2007 Table 34: Johnson & Johnson profile, 2006 Table 35: Johnson & Johnson cancer pipeline, 2007 Table 36: Pfizer profile, 2007 Table 37: Pfizer cancer pipeline, 2007 Table 38: Eli Lilly profile, 2007 Table 39: Eli Lilly cancer pipeline, 2007 Table 40: Merck profile, 2007 Table 41: Merck cancer pipeline, 2007 Table 42: Global cancer market forecasts by drug class, 2005-2012 Table 43: Top 10 cancer drugs forecasts, 2005-2012 Table 44: Top 10 companies by cancer sales forecasts, 2007-2012 Table 45: Top 56 cancer products by global pharmaceutical sales, 2005-2007 Table 46: Top 14 companies by global cancer sales, 2005-2007 Steven Seget is Principal at Delphi Pharma, and provides independent strategic consulting services to the pharmaceutical and biotechnology industries. Steven previously managed the strategic healthcare consulting function at Datamonitor and has an MBA from the London Business School.